Ajanta Pharma Paithan facility gets VAI classification from US FDA

Regulatory & Legal View source PDF Explain this filing

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹3345.10

prior close

₹3326.60

announcement price

In-mkt

timing

Nifty Midcap 150market+0.5%-0.6% vs market

Pharmaceuticals peers, median of 164sector+0.0%-0.2% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.3

15m

+0.3

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.5-0.6+0.0-0.2

Next day

-0.2+0.3-0.5+0.5-0.7

+0.9+0.7+0.2+0.0+0.9

-0.9+0.4-1.3-0.3-0.6

-1.8-1.3-0.6-1.2-0.6

-1.2+0.1-1.3-0.7-0.5

+2.4+1.5+0.9+0.4+2.0

15d

+2.6-0.5+3.1-1.5+4.1

+5.0+2.6+2.4-0.3+5.3

+4.5+1.3+3.3+0.6+3.9

+4.6-4.7+9.3+0.4+4.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ajanta Pharma has received the Establishment Inspection Report (EIR) from the US FDA for its Paithan, Maharashtra manufacturing facility. The cGMP inspection, conducted from 13 April 2026 to 21 April 2026, has been classified as Voluntary Action Indicated (VAI), meaning the facility is in acceptable compliance and no further regulatory action is required. This is a positive regulatory outcome.

Likely market impact

Positive for shareholders: clean US FDA classification removes regulatory overhang and supports continued exports from the Paithan facility.